Skip to main content
. 2021 Apr 2;113(10):1352–1359. doi: 10.1093/jnci/djab065

Table 3.

First disease-free survival event by treatment groupa

Disease-free survival event EC-wP (n = 261) EP-wP (n = 260)
No. (%) No. (%)
Local and regional recurrence 10 (3.8) 7 (2.7)
Distant metastasis 34 (13.0) 23 (8.8)
Contralateral breast tumor 5 (1.9) 4 (1.5)
Second primary malignancy 3 (1.1) 4 (1.5)
Death 1 (0.4) 1 (0.4)
Total 53 (20.2) 39 (14.9)
a

EC-wP = epirubicin/cyclophosphamide followed by weekly paclitaxel; EP-wP = epirubicin/paclitaxel followed by weekly paclitaxel.